CSS LLC’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

CSS LLC’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,300	Closed	-$16K	–	1118
2020 Q4	$16K	Sell	2,300 -1,900	-45%	-$15.3K	﹤0.01%	786
2020 Q3	$46K	Sell	4,200 -1,000	-19%	-$9.15K	﹤0.01%	718
2020 Q2	$33K	Buy	+5,200	New	+$19.9K	﹤0.01%	594

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CSS LLC's SRNE Position: Q2 2022 in Review

CSS LLC sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 7,900 shares — an estimated $18K sold.

CSS LLC first reported a position in SRNE in Q2 2020 and held it in 4 quarters. The position peaked at $142K in Q3 2020. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

CSS LLC reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
CSS LLC sold 7,900 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $18K.
CSS LLC first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
CSS LLC's Sorrento Therapeutics, Inc. position peaked at $142K in Q3 2020.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on CSS LLC's 13F filing for Q2 2022, filed 15 Aug 2022.